Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare CANAGLIFLOZIN (INVOKANA) and Sitagliptin (Januvia) — clinical data, side effects, and patient experiences.
INVOKANA, Invokana · Other
How it works
12.1 Mechanism of Action SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canaglifloz...
Approved for
Januvia, ZITUVIMET · DPP-4 Inhibitor
How it works
Inhibits dipeptidyl peptidase-4 (DPP-4) enzyme, slowing the inactivation of incretin hormones GLP-1 and GIP, thereby increasing insulin release and decreasing glucagon levels in a ...
Approved for
Estimated frequency (%) based on clinical trial data
Based on 26 Reddit discussions
CANAGLIFLOZIN
27%
positive
11 threads
Sitagliptin
40%
positive
15 threads
% of discussions mentioning each side effect
Based on 1 verified patient review
No data yet
No data yet
Avg. Duration
0 months
0% still taking
Avg. Duration
18 months
100% still taking
CANAGLIFLOZIN is a Other, while Sitagliptin belongs to the DPP-4 Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.
Sitagliptin has an average efficacy rating of 7.0/10 and tolerability of 9.0/10 across 1 patient review. Patient-reported outcomes provide real-world context beyond clinical trials, though individual responses to medication vary significantly..
CANAGLIFLOZIN carries 4 FDA warnings. Sitagliptin carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.